Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Synjardy 12.5 mg 1000 mg price?

See the DrugPatentWatch profile for Synjardy

Synjardy (empagliflozin + metformin) is a combination tablet that comes in a 12.5 mg/1 000 mg strength. Because drug pricing varies widely by country, insurance coverage, pharmacy, and whether you’re buying a brand‑name or a generic version, the best way to get an accurate price is to check a few reliable sources:

Source How to use it Typical price range (US, out‑of‑pocket)
Pharmacy benefit manager (PBM) or insurer Log into your pharmacy portal or call your plan’s member services. $90–$170 per month for the brand, often less with a generic (if covered).
Major U.S. pharmacies (CVS, Walgreens, Walmart, etc.) Search for “Synjardy 12.5 mg/1 000 mg” on their online drug price calculators. $110–$150 per month for the brand, $80–$120 for the generic.
Online discount card sites Use a card like GoodRx or Blink Health to compare prices at local pharmacies. Discounts can bring the monthly cost down by 10–30 %.
Manufacturer’s patient assistance program Visit the Novo Nordisk website (the manufacturer of Synjardy) for the “Patient Assistance Program” if you qualify. May provide the medication free or at a very low cost.
Generic alternatives The generic empagliflozin + metformin combination is usually about 20‑30 % cheaper than the brand. $80–$110 per month (depending on dosage).

Quick snapshot (U.S. average)

Formulation Typical retail price (no insurance)
Synjardy 12.5 mg/1 000 mg (brand) $110–$150/month
Generic empagliflozin + metformin 12.5 mg/1 000 mg $80–$110/month

Keep in mind:

  1. Insurance – Most major plans cover Synjardy with a co‑pay (often $10–$25/month) or a co‑insurance (20–35 %).
  2. Pharmacy – Prices can differ by 10‑30 % between chains and independent pharmacies.
  3. State & local assistance – Some states offer free or discounted medications for qualifying patients.
  4. Generic availability – Generic versions have been available in the U.S. since 2024 and are usually 20‑30 % cheaper than the brand.

How to find the exact price for you

  1. Call your pharmacy – “What’s the price for Synjardy 12.5 mg/1 000 mg if I have insurance X?”
  2. Use a price‑comparison site – GoodRx, Blink Health, or PharmacyChecker.
  3. Check the manufacturer’s site – Novo Nordisk offers a patient assistance program that might reduce or eliminate cost if you meet income criteria.

If you let me know your country or insurance details, I can give a more tailored estimate. Otherwise, the figures above should give you a solid baseline for what to expect in the U.S. market.



Other Questions About Synjardy :

Is synjardy better than metformin? Synjardy costo? Synjardy dosing? Where is synjardy manufactured? Synjardy manufacturer coupon 2024? Synjardy and synjardy xr? Cost of synjardy?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The AI response (PASS verdict) accurately states that SYNJARDY/SYNJARDY XR contain a boxed warning for metformin-associated lactic acidosis and that the label provides supporting details and recommended actions, with no contradictions identified.


Category Scores

Warnings
100
Excellent

Accurate Statements

The claim “WARNING: LACTIC ACIDOSIS” is supported because the FDA label includes a boxed warning for metformin-associated lactic acidosis (including fatal cases), with clinical presentation, risk factors, and actions if suspected (immediate discontinuation; prompt hemodialysis recommended).
BOX Lactic Acidosis; Warnings and Precautions (5.1) Lactic Acidosis
The label also includes a dedicated Warnings and Precautions section (5.1) describing metformin-associated lactic acidosis in detail, including risk factors and management steps.
Warnings and Precautions (5.1) Lactic Acidosis

Unsupported Statements


Contradictions


Important Omissions

No specific contraindication language was evaluated in the response (e.g., contraindication for acute/chronic metabolic acidosis including DKA), though it is not required to assess the narrow claim “WARNING: LACTIC ACIDOSIS.”
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The evaluated claim is accurately supported by the boxed warning and label warnings section; no incorrect safety guidance was introduced.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
34
Visibility
33
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • The response does not have pricing data for Synjardy 12.5 mg/1000 mg.
  • Prices for the combination product (empagliflozin + metformin) can vary widely by pharmacy, location, and insurance or programs.
  • Brand pricing can be affected by exclusivity and patent activity over time.
Differentiators

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
CVS 9%
50 #2 No
Walgreens 9%
50 #3 No
Walmart 8%
50 #4 No
DrugPatentWatch 33%
50 #5 No